Lokivetmab

Last updated
Lokivetmab
Monoclonal antibody
Type Whole antibody
Target interleukin 31 (IL-31)
Clinical data
Trade names Cytopoint
Routes of
administration 		subcutaneous injection
ATCvet code
Legal status
Legal status
  • veterinary use
Identifiers
CAS Number
UNII

Lokivetmab, trade name Cytopoint, is a monoclonal antibody used to treat atopic dermatitis in dogs. [1] It acts against interleukin 31 (IL-31), [2] which is a cytokine involved in causing itchiness (pruritus). [2] Lokivetmab is administered by subcutaneous injection; each dose is effective for four to eight weeks. [3]

The United States Department of Agriculture (USDA) approved lokivetmab (manufactured by Zoetis and sold under the trade name Cytopoint) in December 2016, [3] and it was approved by the European Medicines Agency in 2017. [4] Lokivetmab was the first monoclonal antibody to be approved for use in animals in the European Union. [4]

References

  1. ↑ "Zoetis earns license for Cytopoint skin therapy". Veterinary Practice News. 4 January 2017. Retrieved 2018-07-06.
  2. 1 2 Marsella R, De Benedetto A (July 2017). "Atopic Dermatitis in Animals and People: An Update and Comparative Review". Veterinary Sciences. 4 (3): 37. doi: 10.3390/vetsci4030037 . PMC   5644664 . PMID   29056696.
  3. 1 2 McKay L (13 July 2017). "Making a difference for dogs with atopic dermatitis: When to use Apoquel and when to use Cytopoint". dvm360.com. Retrieved 2018-07-07.
  4. 1 2 "First antibody therapy in veterinary medicine launched for dogs in the UK". The Veterinary Record. 181 (1): 6–7. July 2017. doi:10.1136/vr.j3147. PMID   28667135. S2CID   20166012.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.